Batavia Receives Grant to Support Vaccine Availability in Developing Countries
News Jun 14, 2016
Despite many advances in manufacturing technologies in recent years, cost of manufacturing can still present a significant hurdle in the global supply of essential vaccines, such as Polio and Rotavirus vaccines. The work funded by this grant will reduce manufacturing costs of these key vaccines. In its advanced cell-line experience, Batavia Biosciences collaborates with Proventus Bio and their whole genome RNAi screening technology. The RNAi screening data allows Batavia Biosciences to utilize its gene editing technology and cell line expertise. This way, a range of new cell substrates can be generated which will be assessed for its manufacturing performance. Chris Yallop (CSO Batavia Biosciences) expects that “the new cell substrates can significantly increase production yield and thus enhance vaccine availability against reduced costs”.
Menzo Havenga (CEO Batavia Biosciences) adds: “It is extremely rewarding to be working with other best in class partners on a technology development that will have such significant impact in vaccine supply for those in need”.
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE
Staphylococcus epidermidis is an ubiquitous colonizer of healthy human skin, but it is also a notorious source of serious nosocomial infections. Now, a new machine learning technique will help predict the risk of developing a serious, and possibly life-threatening S. epidermidis infection.READ MORE